Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
AssigneeProtemix Corporation Limited
InventorsGarth James Smith Cooper, Anthony Ronald John Phillips, Nancy Xiuyin Chen, Deming Gong, Maria Jullig, Anthony John Rodney Hickey
Life of this patent
Estimating the term…
Abstract
Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen IV, cytochrome C oxidase and erectile dysfunction.
Claims26
A method for increasing copper (I) levels in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for improving age-related physiological deficits and increasing longevity in a mammal comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for delaying mitochondrial dysfunction occurring in a mammal during aging comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for reducing mitochondrial swelling in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for reducing mitochondrial protein mass in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for inhibiting mitochondrial protein expression in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for inhibiting mitochondrial nuclear gene expression in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for reducing mitochondria number in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for reducing TGFβ-1, Smad 4, and/or collagen IV expression in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for reducing mitochondrial cytochrome c release in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for increasing cytochrome c oxidase activity in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
A method for treating erectile dysfunction in a subject comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.